Health
AstraZeneca Faces Setback in Lung Cancer Drug Trial
AstraZeneca is discontinuing a late-stage drug trial for metastatic non-small cell lung cancer. The setback follows a series of recent failures.
Coverage timeline — 1 article
STAT News
AstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacks
2026-08-17 13:22 UTC